trustmebro.to/r/…
✓ checked
trust me, bro:
here is the receipt.
the claim

The intake of estrogens without sufficient gestagens during estrogen replacement therapy is associated with an increased risk of endometrial cancer.

the verdict
SUPPORTED
the evidence backs this
Recorded sources
6 sources for · 0 against

Counts group repeated records of the same source within each side. They do not measure evidence strength or source independence.

Is it true that the intake of estrogens without sufficient gestagens during estrogen replacement therapy is associated with an increased risk of endometrial cancer?

Yes. The intake of estrogens without sufficient gestagens (unopposed estrogen) during hormone replacement therapy or due to other physiological states is strongly associated with an increased risk of endometrial hyperplasia and endometrial cancer.

Verdict: SUPPORTED · 6 sources for, 0 against · Last checked

The analysis

The retrieved literature consistently supports the claim that prolonged exposure to estrogen without adequate progesterone or gestagen counter-regulation (unopposed estrogen) significantly increases the risk of endometrial hyperplasia and endometrial cancer. Multiple sources, including recent reviews and comprehensive systematic analyses, confirm this biological relationship and therapeutic risk.

Evidence for · 6
Endometrial Hyperplasia: Current Insights into Epidemiology, Risk Factors, and Clinical Management.
2025
Identifies extended exposure to unopposed estrogen as a primary cause of endometrial hyperplasia, the direct precursor to endometrial cancer.
Get citation
A, G., S, S., E, M., A, P., A, Z., I, A., K, Z., M, P., D, L., S, M., N, T., M, K., & E, D. (2025). Endometrial Hyperplasia: Current Insights into Epidemiology, Risk Factors, and Clinical Management.. doi.org. https://doi.org/10.3390/cancers18010148

See more details
More for · 5
Sensitive detection of unopposed estrogen using estrogen receptor functionalized nanoprobes for cancer diagnosis.
2026
Notes that unopposed estrogen is strongly implicated in endometrial hyperplasia and type I endometrial carcinogenesis.
Get citation
DE, U., EU, A., CO, O., OP, U., GE, E., IJ, A., M, D., & A, J. (2026). Sensitive detection of unopposed estrogen using estrogen receptor functionalized nanoprobes for cancer diagnosis.. doi.org. https://doi.org/10.1186/s11671-026-04831-z

Endometrial cancer in a young nulliparous woman: a case report.
2026
Links prolonged unopposed estrogen exposure to the development of endometrial cancer in young women presenting with abnormal bleeding.
Get citation
HM, R., A, I., J, M., & EI, E. (2026). Endometrial cancer in a young nulliparous woman: a case report.. doi.org. https://doi.org/10.4082/kjfm.25.0163

Hormone therapy in postmenopausal women and risk of endometrial hyperplasia or endometrial cancer.
2025
Confirms through systematic review evidence that unopposed estrogen significantly increases the risk of endometrial hyperplasia compared to placebo or combined regimens.
Get citation
D, K., V, J., F, C., M, F., A, H., M, B. R., & MR, W. (2025). Hormone therapy in postmenopausal women and risk of endometrial hyperplasia or endometrial cancer.. doi.org. https://doi.org/10.1002/14651858.cd000402.pub5

Endometrial hyperplasia as a risk factor of endometrial cancer.
2022
States that chronic exposure to unopposed estrogen is the most important risk factor for the development of endometrial hyperplasia and subsequent cancer.
Get citation
Nees, L. K., Heublein, S., Steinmacher, S., Juhasz-Böss, I., Brucker, S., Tempfer, C. B., & Wallwiener, M. (2022). Endometrial hyperplasia as a risk factor of endometrial cancer.. doi.org. https://doi.org/10.1007/s00404-021-06380-5

Endometrial Cancer: Rapid Evidence Review.
2025
Lists unopposed estrogen states among the key established risk factors for endometrial cancer.
Get citation
Bryce, C., Gazda, R., & Fuerst, H. (2025). Endometrial Cancer: Rapid Evidence Review.. pubmed.ncbi.nlm.nih.gov. https://pubmed.ncbi.nlm.nih.gov/40531151/

What does the evidence say?

The retrieved literature consistently supports the claim that prolonged exposure to estrogen without adequate progesterone or gestagen counter-regulation (unopposed estrogen) significantly increases the risk of endometrial hyperplasia and endometrial cancer. Multiple sources, including recent reviews and comprehensive systematic analyses, confirm this biological relationship and therapeutic risk.

Receipt History
Anyone with this link can read the claim and its public receipt, including any personal information in that text. Open permanent receipt.
Check your own claim
Challenge the receipt
Requests are recorded for review. This does not start an automatic check or guarantee a response time.

See the evidence timeline

Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.

This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work